[EN] PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES<br/>[FR] COMPOSES PYRROLIQUES DESTINES AU TRAITEMENT DE MALADIES INDUITES PAR PROSTAGLANDINE
申请人:GLAXO GROUP LTD
公开号:WO2003101959A1
公开(公告)日:2003-12-11
Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.
Simple Access to Elusive α-Boryl Carbanions and Their Alkylation: An Umpolung Construction for Organic Synthesis
作者:Kai Hong、Xun Liu、James P. Morken
DOI:10.1021/ja505455z
日期:2014.7.30
The reaction of 1,1-bis(pinacolboronate) esters with alkyl halides can be effected by metal alkoxides and provides a strategy for the construction of organoboronate compounds. The reaction is found to occur by alkoxide-induced deborylation and generation of a boron-stabilized carbanion.
Aliphatic and aromatic aldehydes have been converted into 1,1-dibromoalkyl derivatives using a 1:1 mixture of triphenyl phosphite and bromine as reagent.
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742
作者:Wensheng Yu、Craig A. Coburn、Anilkumar G. Nair、Michael Wong、Ling Tong、Michael P. Dwyer、Bin Hu、Bin Zhong、Jinglai Hao、De-Yi Yang、Oleg Selyutin、Yueheng Jiang、Stuart B. Rosenblum、Seong Heon Kim、Brian J. Lavey、Guowei Zhou、Razia Rizvi、Bandarpalle B. Shankar、Qingbei Zeng、Lei Chen、Sony Agrawal、Donna Carr、Laura Rokosz、Rong Liu、Stephanie Curry、Patricia McMonagle、Paul Ingravallo、Fred Lahser、Ernest Asante-Appiah、Amin Nomeir、Joseph A. Kozlowski
DOI:10.1016/j.bmcl.2016.05.041
日期:2016.8
HCVNS5Ainhibitors have demonstrated impressive in vitro potency profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed dose combination regimen for the treatment of HCV infection. Herein we describe our continued research efforts around the alkyl “Z group” modification of the tetracyclic indole-based NS5A